Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

UNICYCIVE THERAPEUTICS, INC.

(UNCY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Recovering in Afternoon Trade

07/13/2021 | 01:42pm EST


ę MT Newswires 2021
All news about UNICYCIVE THERAPEUTICS, INC.
11/29UNICYCIVE THERAPEUTICS : Receives Confirmatory Guidance on Renazorb Regulatory Pathway - F..
PU
11/29UNICYCIVE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/29Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory Pathway
PR
11/29Unicycive Therapeutics, Inc. Receives Confirmatory Guidance on Renazorb Regulatory Path..
CI
11/12Unicycive Therapeutics Announces Third Quarter 2021 Financial Results - Form 8-K
PU
11/12UNICYCIVE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
11/11Unicycive Therapeutics Announces Third Quarter 2021 Financial Results
PR
10/26Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate..
PR
10/26Unicycive Therapeutics, Inc. Appoints Douglas Jermasek as Executive Vice President, Cor..
CI
09/20UNICYCIVE THERAPEUTICS, INC.(NASDAQC : UNCY) added to S&P TMI Index
CI
More news
Analyst Recommendations on UNICYCIVE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -8,98 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,85x
Yield 2021 -
Capitalization 27,1 M 27,1 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 1
Free-Float 60,4%
Chart UNICYCIVE THERAPEUTICS, INC.
Duration : Period :
Unicycive Therapeutics, Inc. Technical Analysis Chart | UNCY | US90466Y1038 | MarketScreener
Technical analysis trends UNICYCIVE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,81 $
Average target price 13,25 $
Spread / Average Target 632%
EPS Revisions
Managers and Directors
Shalabh Gupta Chairman, President & Chief Executive Officer
John W. Townsend Chief Financial Officer
Pramod K. Gupta Executive VP-Pharmaceutical & Business Operations
John L. Ryan Independent Director
Sandeep Laumas Independent Director
Sector and Competitors
1st jan.Capi. (M$)
UNICYCIVE THERAPEUTICS, INC.0.00%27
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298